Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development, 2021

November 2021 | 123 pages | ID: N6D41FAEE2A0EN
Global Markets Direct

Abstracts

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development, 2021

SUMMARY

According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 - Drugs In Development, 2021'; NonReceptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 31 molecules.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

The report 'Non Receptor Tyrosine Protein Kinase TYK2 - Drugs In Development, 2021' outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 9, 12 and 3 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Oncology, Central Nervous System, Infectious Disease, Metabolic Disorders and Respiratory which include indications Psoriasis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Plaque Psoriasis (Psoriasis Vulgaris), Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Psoriatic Arthritis, Alopecia Areata, Coronavirus Disease 2019 (COVID-19), Hidradenitis Suppurativa, Inflammation, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Vitiligo, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Neuroinflammation, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified Immunological Disorders and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
• The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Atomwise Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Esker Therapeutics Inc, 2021
Pipeline by Galapagos NV, 2021
Pipeline by Haisco Pharmaceutical Group Co Ltd, 2021
Pipeline by InnoCare Pharma Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neuron23 Inc, 2021
Pipeline by Nimbus Therapeutics LLC, 2021
Pipeline by Oncostellae SL, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Sareum Holdings Plc, 2021
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
Pipeline by Simcere Pharmaceutical Group Ltd, 2021
Pipeline by Technoderma Medicines Inc, 2021
Pipeline by Theravance Biopharma Inc, 2021
Pipeline by TLL Pharmaceutical LLC, 2021
Pipeline by Ventyx Biosciences Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021